Treatment Update for Hormone Receptor-Positive Advanced Breast Cancer

LONDON, December 15, 2016 /PRNewswire/ --

Karen A Gelmon, European Oncology & Haematology, 2016;12(2):79-80 DOI: https://doi.org/10.17925/EOH.2016.12.02.79

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Karen A Gelmon draws attention to the urgent need for new treatments for advanced cancer of the breast, of which the most common subtype is hormone receptor positive breast cancer. In the randomised, double-blind, multicentre phase III trial, Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON), a statistically significant 21% reduction in the risk of disease progression or death was reported in women with hormone receptor-positive advanced breast cancer who had been treated with fulvestrant compared with those who had received anastrozole. Women in this study had not received prior hormone therapy. Access to the treatment and the mechanisms for funding need to be facilitated in a timely fashion. Ongoing studies are awaited to help define the optimal sequence of therapy for women with hormone receptor-positive advanced breast cancer.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/EOH.2016.12.02.79

Disclosure: Karen Gelmon has nothing to disclose in relation to this article. This article is a short opinion piece and has not been submitted to external peer reviewers, but the questions were reviewed by the Editorial Board before publication.

Note to the Editor

touchONCOLOGY (a division of Touch Medical Media) publishes

European Oncology & Haematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and haematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchONCOLOGY.com

For inquires please contact:
Nicola Cartridge - Managing Editor
[email protected]
T: +44-(0)207-193-3186
Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchONCOLOGY.com